trans-Doxercalciferol

trans-Doxercalciferol is an isomer of Doxercalciferol (HY-32348). Doxercalciferol is a vitamin D receptor agonist. Doxercalciferol reduces proteinuria, podocyte injury, mesangial expansion, extracellular matrix accumulation, macrophage infiltration, oxidative stress, proinflammatory cytokines, profibrotic growth factors, renal neutral lipid accumulation, albuminuria and glomerulosclerosis. Doxercalciferol alleviates high-salt diet-induced myocardial hypertrophy. trans-Doxercalciferol is used for the research of diet-induced obesity-related nephropathy, diabetic nephropathy, myocardial hypertrophy, cardiac dysfunction and secondary hyperparathyroidism^{[1][2][3][4][5]}. In Vivo:Doxercalciferol (0.4-0.6 μg/kg; i.p.; 3 times per week; 4-20 weeks) exerts comparable renoprotective efficacy to Losartan (HY-17512) in diabetic mice^[2].
Doxercalciferol (150-250 ng; intraperitoneal injection; three times per week; for 6 consecutive weeks) alleviates high-salt diet-induced myocardial hypertrophy, improves cardiac dysfunction, reduces the levels of hypertrophy biomarkers, and inhibits PKCα activation in male DSS rats, without causing significant changes in serum Ca²⁺ levels^[3].